KR20110000323A - Pharmaceutical and health food composition for preventing and treating diabetes mellitus comprising fruit extracts of chaenomeles sinensis as effective component - Google Patents

Abstract

PURPOSE: A pharmaceutical composition and health food containing Chaenomeles sinensis fruit extract for preventing and treating diabetes is provided to suppress alpha-glucosidase, beta-glucosidase, alpha-galactosidase, and beta-galactosidase and to be used as a therapeutic agent for enzyme-associated diabetes. CONSTITUTION: A pharmaceutical composition for preventing and treating diabetes contains Chaenomeles sinensis fruit solvent extract as an active ingredient. The Chaenomeles sinensis fruit is dried or raw fruits. The solvent extract is isolated using water, low alcohol of C1-C4 or mixture solvent thereof. A health food for preventing and treating diabetes contains the Chaenomeles sinensis solvent extract as an active ingredient.

Description

Pharmaceutical and health food composition for preventing and treating diabetes mellitus comprising fruit extracts of Chaenomeles sinensis as effective component}

The present invention relates to a pharmaceutical composition for preventing and treating diabetes and a health functional food containing the Chinese quince fruit extract as an active ingredient.

Diabetes mellitus (DM) is a life-threatening major chronic disease caused by improperly regulated homeostasis of carbohydrate and lipid metabolism resulting in increased blood glucose. DM is a serious metabolic disease that has a significant impact on the patient's health, quality of life and longevity, and the healthcare system. According to the WHO, at least 170 million people worldwide now have diabetes, and this number is expected to more than double in 2030, with approximately 3.2 million people dying from diabetes complications each year; 6 deaths per minute (WHO, 2007. www.who.int/dietphysicalactivity/publications/facts/diabetes/en/).

Diabetes mellitus has insulin dependency (type I) and insulin independent (type II), of which type II is the more frequent form, and the incidence of diabetes increases with the increase in obesity and aging (Kim et al. 2004. Carbohydr.Res., 339: 715-717). In recent years, there has been a growing interest in the treatment of DM with herbal medicines, because herbal medicines are generally non-toxic, and WHO has recommended treatment with traditional plants in the absence of safe modern drugs in underdeveloped countries. Plant derivatives with hypoglycemic properties have long been used as indigenous drugs (Yeh et al. 2003. Diabetes Care, 26: 1277-1294). Despite the introduction of natural and synthetic hypoglycemic agents, diabetes mellitus and its secondary complications have been a major medical problem for people (Ravi et al. 2005. Food Chem. Toxicol., 43: 1433-1439). Medicinal plants, which have traditionally been used for the treatment of hyperglycemia, have been recognized that different parts of the plant contain anti-diabetic activity, and research on the development of anti-diabetics is very active. It has been developed and is still being searched and developed for anti-diabetic and preventive drugs targeting new plants.

In the present invention, the effects of Korean medicinal plant extracts on various enzymes (eg, α-glucosidase, β-glucosidase, α-galactosidase and β-galactosidase) were investigated. The enzymes are involved in various biochemical processes related to metabolic diseases and diseases such as diabetes, viral or bacterial infections, lysosomal storage disorders and cancer. Thus, research has been underway for a long time to search for better glycosidase inhibitors, and as a result, the Chinese quince was selected as a plant containing an excellent inhibitor to investigate the additional properties of the quince. (Naumov, D., 2004. Mol. Biol. (Mosk), 38: 388-399).

Chaenomeles sinensis (Thouin) Koehne (also called Pseudocydonia sinensis (Thouin) CK Schneid), a plant belonging to the Rosaceae family, is commonly distributed in Korea, China, and Japan. do. The fruit appeared to have a large amount of phenolics. This high phenolic content can be expected to act as a health improving factor (Hamauzu et al. 2006. J. Agric. Food Chem., 54: 765-772). Its fruit is used as a traditional Chinese medicine to treat throat disorders. In addition, anti-influenza, antioxidant, anti-ulcer, antiviral, antihemolytic, anti-itch and antibacterial (to Streptococcus pyogenes , the causative agents of tonsillitis and pharyngitis) have been reported in this fruit (Hamauzu et al. 2006. J. Agric.Food Chem., 54: 765-772).

Korean Patent Registration No. 10-0540033 discloses a herbal composition for treating arthritis containing a Chinese quince and other ingredients as an active ingredient, and a method of manufacturing the same. Korean Patent Publication No. 2006-0085731 includes Chinese quince extract and other extracts. Disclosed is a composition for inhibiting alcohol absorption.

The present invention has been made in accordance with the above requirements, and thus there is no previous patent discussed about antidiabetic activity of quince, so in the present invention, crude extracts of quince through study of inhibition of various enzymes including glycosidase and By investigating the antidiabetic potential of various fractions thereof, the Chinese quince fruit extract is intended to be used as a prophylactic and therapeutic agent for diseases related to the enzyme.

In order to solve the above problems, the present invention provides a pharmaceutical composition for the prevention and treatment of diabetes mellitus containing quince fruit extract as an active ingredient.

The present invention also provides a dietary supplement for preventing and improving diabetes containing the extract as an active ingredient.

According to the present invention, the Chinese quince fruit extract of the present invention inhibited α-glucosidase, β-glucosidase, α-galactosidase and β-galactosidase. Thus, the Chinese quince fruit extract can be used as a symptomatic or therapeutic agent for diabetes related to the enzyme.

In order to achieve the object of the present invention, the present invention provides a pharmaceutical composition for the prevention and treatment of diabetes mellitus containing a solvent extract of the fruit of Chaenomeles sinensis .

In the pharmaceutical composition of the present invention, the solvent may be various organic solvents including water, C1 to C4 lower alcohols such as methanol, ethanol, butanol, and the like, mixed solvents thereof, and the like.

In the pharmaceutical composition of the present invention, the solvent extract is obtained by soluble fraction obtained using various nonpolar solvents including water and butanol, ethyl acetate, hexane, methylene chloride and the like, or higher obtained using various chromatographic techniques. Fractions of purity can inhibit α-glucosidase and water soluble fractions of the solvent extracts can inhibit β-glucosidase.

The present invention also provides a dietary supplement for preventing and improving diabetes containing a solvent extract of Chaenomeles sinensis fruit as an active ingredient.

Hereinafter, the present invention will be described in more detail.

The crude extract of Chinese quince comprises water and C1 to C4 lower alcohols such as methanol, ethanol, butanol and the like, mixed solvents thereof, and various organic solvents, preferably extracts available in methanol.

In addition, the quince fruit nonpolar solvent soluble fraction includes fractions soluble in various nonpolar solvents including hexane, chloroform, methylene chloride or ethyl acetate.

In addition, the quince fruit polar solvent soluble fraction includes those extracted with various polar solvents, preferably butanol, including acetone, butanol, ethanol, methanol or water.

The quince fruit crude extract, nonpolar solvent soluble fraction and polar solvent soluble fraction of the present invention are fruits of the previous stage including, for example, young fruits (dried or raw) and mature fruits (dried or raw) of quince. Can be obtained as follows.

After cutting the quince fruit of the present invention as a whole or in small pieces or grinding into a crusher, and finely powdered, the volume of water between 0.1 and 50 times the weight of the quince fruit and lower levels of C1 to C4 such as methanol, ethanol, butanol, etc. Hydrothermal extraction, cooling with alcohol or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10 and other organic solvents, preferably about 5 to 80 ° C., preferably about 24 ° C., for about 2 months with various organic solvents. After extraction using various extraction methods including extraction, reflux cooling extraction, ultrasonic extraction, supercritical extraction, etc., the filtrate is recovered by vacuum filtration, and the above procedure is repeated 1 to 5 times, preferably 2 times. The filtrate was collected and concentrated under reduced pressure to obtain a crude extract of Chinese quince.

In addition, the quince fruit nonpolar solvent soluble fraction of the present invention is prepared by suspending the crude fruit extract of the quince in distilled water, and then, about 1 to 100 times the volume of these suspensions, preferably about 1 to 55 times the volume of hexane, ethyl acetate, and methylene. Various nonpolar solvents including chloride, chloroform, butanol and the like can be added to extract and separate the soluble layers of the nonpolar solvent from 1 to 10 times, preferably from 2 to 5 times. In addition, conventional fractionation processes can also be performed (Harborne J. B. Phytochemical methods: A guide to modern techniques of plant analysis, 3rd Ed., Pp 6-7, 1998).

More preferably, the crude Chinese quince extract obtained by the above process, preferably the Chinese quince fruit methanol extract is dissolved in water, and then the aqueous solution and various organic solvents including n-butanol, ethyl acetate, methylene chloride, hexane, etc. have low polarity. After sequentially mixing the solvent in the order of high polar solvent, preferably hexane, methylene chloride, ethyl acetate, n-butanol, water and then sequentially fractionated the solvent, concentrated under reduced pressure and concentrated quince fruit hexane, ethyl acetate, methylene Chloride, n-butanol fractions can be obtained.

The present invention provides a pharmaceutical composition for the prevention and treatment of diabetes mellitus containing the crude extract of Chinese quince, the nonpolar solvent soluble fraction and the polar solvent soluble fraction obtained as the active ingredient. The diabetes may preferably be type II diabetes.

In addition, the Chinese quince has been used as a herbal medicine for a long time, the extracts of the present invention extracted therefrom also have no problems such as toxicity and side effects.

It was confirmed that the quince fruit methanol extract and each solvent fraction obtained by the above method inhibited α-glucosidase, β-glucosidase, α-galactosidase and β-galactosidase.

The pharmaceutical composition for preventing and treating diabetes of the present invention may include 0.02 to 50% by weight of the extract based on the total weight of the composition.

Pharmaceutical compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

The pharmaceutical dosage forms of the extracts of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.

Pharmaceutical compositions comprising extracts according to the invention, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be formulated and used. Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate And various compounds or mixtures including cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate and sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

The extract of the present invention can be administered to mammals such as rats, mice, livestock, humans and the like in various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

In addition, the present invention provides a health functional food comprising the Chinese quince fruit extract and food acceptable food supplements exhibiting a prevention and improvement effect of diabetes. The Chinese quince fruit extract is preferably a supercritical extract using ethanol extract and carbon dioxide. Examples of the food to which the extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.

It may also be added to foods or beverages for the purpose of preventing and improving diabetes. At this time, the amount of the extract in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1g based on 100 ml. have.

The health functional beverage composition of the present invention has no particular limitation on the other ingredients other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract, for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. . The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition to the above, the extract of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extracts of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components may be used independently or in combination, and the proportion of such additives is not so critical but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.

Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

Materials and methods

Plant material

The dried and mature fruits of the Chinese quince were obtained from the Korean biotech company "Korean Collection of Herbal Extracts." The guarantee samples of the above plants are stored in the Medicinal Resources Collection, Inc. (Korea Collection of Herbal Extracts, 2000).

extraction

The dried and ripe fruit was cut into small pieces and ground into fine powder. Powdered Chinese quince fruits (2 Kg, dry weight) were soaked for 2 months at room temperature after adding 80% methanol. Subsequently, the extract was concentrated at 20-30 ° C. using a rotary vacuum concentrator to obtain dried crude extract (210 g).

Fraction

Methanol crude extract (210 g) was suspended in distilled water (1 L) and fractionated with n-hexane, methylene chloride, ethyl acetate and n-butanol to give n-hexane (17 g), methylene chloride (12 g), Ethyl acetate (26 g), n-butanol (77 g) and aqueous (64 g) fractions were obtained. Enzyme Inhibitory Activity Assay 500 ㎍ / mL for Crude Extracts and Various Fractions It was performed using the concentration.

reagent

α-glucosidase (from Saccharomyces cerevisiae type I), β-glucosidase (from almonds), α-galactosidase (from green coffee beans), β-galactosida Aze (from E. coli), 4-nitrophenyl α-D-glucopyranoside, 4-nitrophenyl β-D-glucopyranoside, 4-nitrophenyl α-D-galactopyranoside, 2-nitrophenyl β-D-galactopyranoside was purchased from Sigma-Aldrich (St. Louis, Mo., USA). Other commercial reagents and solvents were used.

Enzyme analysis

The previously reported methods of enzyme inhibitory activity against α-glucosidase, β-glucosidase, α-galactosidase and β-galactosidase (Shibano et al. 1997. Chem. Pharm. Bull., 45: 700-775) with a slight modification.

α-glucosidase assay

The reaction mixture consists of 50 μl 0.1 M phosphate buffer (pH 7.0), 25 μl 0.5 mM 4-nitrophenyl α-D-glucopyranoside (soluble in 0.1 M phosphate buffer, pH 7.0), 10 μl sample (concentration). : to 500 ㎍mL ^-1) and of 25 ㎕ α- glucosidase solution (0.01 M phosphate buffer, pH 7.0 in the stock solution 1 mgmL ^-1 just before analysis with the same buffer of pH 7.0 was diluted with 0.04 mL Units ^-1 ) The reaction mixture was then incubated at 37 ° C. for 30 minutes. The reaction was then terminated by addition of 100 μl 0.2 M sodium carbonate solution. Enzymatic hydrolysis of the substrate was analyzed by measuring the absorbance at 410 nm using a microplate reader to determine the amount of p-nitrophenol released in the reaction mixture. All experiments were performed in 3 replicates.

β-glucosidase assay

The reaction mixture was prepared with 50 μl 0.1 M phosphate buffer (pH 7.0), 25 μl 0.5 mM 4-nitrophenyl β-D-glucopyranoside (dissolved in 0.1 M phosphate buffer, pH 7.0), 10 μl sample (concentration). : 500 μg mL- ¹ ) and 25 μl of β-glucosidase solution (0.01 M phosphate buffer, 1 mgmL- ¹ of stock solution in pH 7.0, diluted 0.04 Units mL- ¹ with the same buffer at pH 7.0 immediately before analysis) It was made). The reaction mixture was then incubated at 37 ° C. for 30 minutes. The reaction was then terminated by addition of 100 μl 0.2 M sodium carbonate solution. Enzymatic hydrolysis of the substrate was analyzed by measuring the absorbance at 410 nm using a microplate reader to determine the amount of p-nitrophenol released in the reaction mixture. All experiments were performed in 3 replicates.

α-galactosidase assay

The reaction mixture was prepared with 50 μl 0.1 M phosphate buffer (pH 7.0), 25 μl 0.5 mM 4-nitrophenyl α-D-galactopyranoside (dissolved in 0.1 M phosphate buffer, pH 7.0), 10 μl sample ( concentration to 500 ㎍ mL ^-1) and 25 ㎕ α- galactosidase solution (0.01 M phosphate buffer, the same buffer having a pH of 0.04 Units mL ^-1 stock solution pH 1 to 7.0 in 7.0 mgmL ^-1 just prior to analysis Diluted). The reaction mixture was then incubated at 37 ° C. for 30 minutes. The reaction was then terminated by addition of 100 μl 0.2 M sodium carbonate solution. Enzymatic hydrolysis of the substrate was analyzed by measuring the absorbance at 410 nm using a microplate reader to determine the amount of p-nitrophenol released in the reaction mixture. All experiments were performed in 3 replicates.

β-galactosidase assay

The reaction mixture was prepared with 50 μl 0.1 M phosphate buffer (pH 7.0), 25 μl 0.5 mM 2-nitrophenyl β-D-galactopyranoside (dissolved in 0.1 M phosphate buffer, pH 7.0), 10 μl sample ( concentration to 500 ㎍ mL ^-1) and 25 ㎕ β- galactosidase solution (0.01 M phosphate buffer, the same buffer having a pH of 0.04 Units mL ^-1 stock solution pH 1 to 7.0 in 7.0 mgmL ^-1 just prior to analysis Diluted). The reaction mixture was then incubated at 37 ° C. for 30 minutes. The reaction was then terminated by addition of 100 μl 0.2 M sodium carbonate solution. Enzymatic hydrolysis of the substrate was analyzed by measuring the absorbance at 410 nm using a microplate reader to determine the amount of o-nitrophenol released in the reaction mixture. All experiments were performed in 3 replicates.

Statistical analysis

All analyzes were performed at least three times in three replicates. Inhibition rates for all assays were calculated as percentage of control (inhibitor containing MeOH) without inhibitor. All results are expressed as mean W SD.

Example 1 Diabetes-Related Enzyme Inhibitory Effect of the Chinese Quince Extract

The crude extracts of the quince and various fractions thereof were evaluated at 5 μg / 210 μl concentrations for the α-glucosidase, β-glucosidase, α-galactosidase and β-galactosidase enzyme inhibition studies.

All quince extracts showed significant α-glucosidase inhibitory activity (at concentrations of 5 μg / 210 μl reaction) in the range of 82-99% (FIG. 1): n-butanol (99%)> water (97%) > Ethyl acetate (92%)> n-hexane (91%)> crude extract (89%)> methylene chloride (82%).

In addition, β-glucosidase inhibition results are as follows: water (85%)> crude extract (58%)> ethyl acetate (48%)> methylene chloride (40%)> n-butanol (37%)> n- Hexane (5%). It only shows significant β-glucosidase inhibitory activity in the water extract (FIG. 2).

Less significant α-galactosidase (18-35%) and β-galactosidase (10-34%) inhibition were investigated in all quince fractions (Figures 3 and 4).

Hereinafter, an example of the preparation of a pharmaceutical composition including the extract of the present invention will be described, but the present invention is not intended to limit the present invention, but is intended to be described in detail.

Formulation Example 1 Preparation of Powder

Chinese quince extract powder 20 mg

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2: Preparation of Tablet

Chinese quince extract powder 10 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

Formulation Example 3: Preparation of Capsule

Chinese quince extract powder 10 mg

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium Stearate 0.2 mg

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation Example 4 Preparation of Injection

Chinese quince extract powder 10 mg

Mannitol 180 mg

Sterile distilled water for injection 2974 mg

_{Na 2 HPO 4 · 12H 2 O} 26 mg

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

Formulation Example 5 Preparation of Liquid

Chinese quince extract powder 20 mg

10 g per isomer

5 g mannitol

Purified water quantity

According to the conventional method for preparing a liquid, each component is added and dissolved in purified water, lemon flavor is added, the above components are mixed, purified water is added, the whole is adjusted to 100 ml by adding purified water, and then filled in a brown bottle. The solution is prepared by sterilization.

Formulation Example 6 Preparation of Healthy Drinks

Chinese Quince Extract Powder 100mg

15 g of vitamin C

100 g of vitamin E (powder)

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B ₁ 0.25 g

Vitamin B ₂ 0.3 g

Water quantification

After mixing the above components according to a conventional healthy beverage manufacturing method, using a high pressure vessel for about 1 hour and heated between 100 ℃ and 130 ℃, the resulting solution is filtered and obtained in a sterilized 2 L container and sealed After sterilization and refrigerated, it is used to prepare a healthy beverage composition of the present invention.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

1 is a result of α-glucosidase inhibition by the crude extract of quince and fractions thereof at a concentration of 5 μg / 210 μl.

FIG. 2 shows the results of β-glucosidase inhibition by crude extracts of quince and fractions thereof at a concentration of 5 μg / 210 μl.

Figure 3 is the result of α-galactosidase inhibition by the crude extract of quince and fractions thereof at a concentration of 5 μg / 210 μl.

Figure 4 shows the results of β-galactosidase inhibition by the crude extract of quince and fractions thereof at a concentration of 5 μg / 210 μl.

Claims (7)

A pharmaceutical composition for the prevention and treatment of diabetes mellitus containing the solvent extract of the fruit of Chaenomeles sinensis . The pharmaceutical composition for preventing and treating diabetes of claim 1, wherein the fruit is a fruit of all stages including dried or raw young fruits or mature fruits. According to claim 1, wherein the solvent extract is a pharmaceutical composition for the prevention and treatment of diabetes, characterized in that the extraction using water, C1 to C4 lower alcohol, or a mixed solvent thereof. The method of claim 1, wherein the extract is cut into whole or small pieces of quince fruit or ground by grinding with a fine powder, followed by extraction using hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction or supercritical extraction. Pharmaceutical composition for the prevention and treatment of diabetes, characterized in that obtained by. The method of claim 3, wherein the aqueous solution of the solvent extract is mixed with butanol, methylene chloride, ethyl acetate, or hexane and subsequently layered to obtain an soluble fraction of the solvent or higher purity obtained using a chromatography technique. A pharmaceutical composition for the prevention and treatment of diabetes, characterized in that the fraction inhibits α-glucosidase. The pharmaceutical composition for preventing and treating diabetes of claim 3, wherein the water-soluble fraction of the solvent extract inhibits β-glucosidase. Health functional food for diabetes prevention and improvement containing solvent extract of Chaenomeles sinensis fruit as an active ingredient.

Images